Following the successful completion of a Phase IIa study in Australia for its lead asset TTAC-0001 (tanibirumab) for recurrent glioblastoma, South Korea's PharmAbcine Inc. is set to launch diverse clinical trials for the fully humanized therapeutic antibody as well as for other pipeline assets, for some of which research and collaboration deals with Merck & Co. Inc. have already been agreed.
The Korean firm's main emphasis at present is on TTAC-0001, and a relative lack of side-effects and adverse reactions in...